NIFTY200 Alpha 30

As a further update to its intimations and clarifications dated November 21, 2024, November 27, 2024, January 23, 2026, January 24, 2026, January 31, 2026, April 8, 2026, April 18, 2026 and May 15, 2026. In relation to the civil complaint (No. 24-CV-08080) filed before the United States District Court for the Eastern District of New York (‘US Eastern District NY Court’) by the United States Securities and Exchange Commission (‘US SEC’) against Gautam Adani and Sagar Adani, Adani Green Energy has informed that the US Eastern District NY Court has entered a final judgment, on consent, on August 10, 2026. Details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2023 (as updated on January 30, 2026) are as disclosed in Annexure A. As mentioned earlier, the Company is not a party to this proceeding, and no charges have been brought against it.

The above information is a part of company’s filings submitted to BSE.  

Glenmark Pharmaceuticals has informed that the Company has allotted 23,863 Equity Shares of Re 1 each on August 10, 2026, to the grantee who had exercised the options under the Company's Employee Stock Option Plan 2016 (ESOP 2016). With this allotment, the paid-up capital of the Company has increased from Rs 28,22,00,809 divided into 28,22,00,809 number of equity shares of face value Re 1 each to Rs. 28,22,24,672 divided into 28,22,24,672 number of equity shares of face value Re 1 each. The details as required under the SEBI (Share Based Employee Benefits and Sweat equity) Regulations, 2021 are enclosed as Annexure - I.

The above information is a part of company’s filings submitted to BSE.  

With reference to earlier intimations regarding the filing of a ‘short-form’ and subsequently, a ‘long-form’ declaration with the Committee on Foreign Investment in the United States [‘CFIUS’] in connection with the proposed acquisition of AluChem Companies, Inc, Hindalco Industries has informed that due to partial shutdown of the U.S. federal government, the statutory timelines under the CFIUS review framework were tolled, thereby impacting the ongoing CFIUS review process. The matter, however, is progressing and is anticipated to reach finality by September 2, 2026. This timeline remains subject to receipt of final clearance. The company will provide further updates as and when material developments occur or upon completion of the review process. All other details, as per its referred intimations, remain unchanged. This is also made available on the website of the Company www.hindalco.com.